In the last few years, there have been growing calls to onshore the manufacturing of certain pharma products, including active pharmaceutical ingredients (API), to ensure a smooth supply and to minimise shortages in the European Union (EU). In this month’s cover story, we explore what this ‘reshoring’ might look like amidst rising inflation and how to get these plans right in the EU.

Also in this month’s issue, we take a look at the innovative type 1 diabetes therapy by Provention Bio called Tzield. More than a century after an individual with type 1 diabetes was treated with insulin for the first time, the FDA approved Tzield, the first and only treatment to delay the onset of type 1 diabetes. But experts tell us that wider screening programs are needed to address existing inequities in this space and to ensure all eligible patients get access to this treatment. 

Don’t miss an in-depth feature looking at the latest trends in decentralised clinical trials, and the story behind the development of Alzheimer’s disease vaccines.

All this, and the latest pharma industry news, comment, and analysis from GlobalData.

Read the latest issue of Pharma Technology Focus for all this and more news, insights, and analysis from the pharmaceutical industry.

You can also subscribe here to receive email notifications when a new issue is available.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.